Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from NexGel Inc ( (NXGL) ) is now available.
On March 6, 2026, NEXGEL, Inc. entered into an asset purchase and exclusive license agreement with Celularity, Inc. to acquire an exclusive license to Celularity’s commercial-stage regenerative biomaterials portfolio and related assets, focused on tendon repair, skin grafts and bone growth. The deal, valued at up to $35 million in cash with a $15 million upfront payment and up to $20 million in milestone-based payments, also anticipates ancillary manufacturing and sublease arrangements and is conditioned on NEXGEL securing sufficient financing for the upfront consideration.
Announced publicly on March 10, 2026, the transaction is described by NEXGEL as the most significant milestone in its history and is expected to roughly triple annual revenue to about $35 million and make the company profitable upon closing. The portfolio comprises six established, revenue-generating regenerative biomaterial products with existing insurance reimbursement and more than a decade of clinical use, alongside a planned pipeline of three new 510(k) filings in 2026, 2027 and 2028, and includes the addition of an experienced commercial and scientific team that is expected to expand NEXGEL’s sales reach and strengthen its position as a meaningful participant in the medical technology market.
In connection with the deal, NEXGEL plans to close approximately $14.9 million in additional financing in the first half of 2026 to help fund the upfront payment and support integration. The company is also in talks with an accredited institutional investor about an equity line of credit facility of up to $100 million in newly issued common shares, which would provide flexible growth capital and underpin its strategy of scaling a combined regenerative biomaterials and hydrogel platform across multiple verticals.
The most recent analyst rating on (NXGL) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
Spark’s Take on NXGL Stock
According to Spark, TipRanks’ AI Analyst, NXGL is a Neutral.
The score is driven primarily by still-weak financial fundamentals (ongoing losses and negative free cash flow) despite improving margins and prior revenue scaling. Technicals are mixed with the stock below key longer-term moving averages. Guidance and partnerships support a better near-term outlook, but flat recent revenue and partnership/logistics uncertainties temper confidence, and valuation metrics provide limited support due to negative earnings.
To see Spark’s full report on NXGL stock, click here.
More about NexGel Inc
NEXGEL, Inc. is a Langhorne, Pa.-based provider of healthcare, beauty and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogel technologies for healthcare and consumer applications. The company has manufactured electron-beam, cross-linked hydrogels for over two decades and markets brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm and Silly George, while also maintaining strategic contract manufacturing relationships with leading consumer healthcare companies.
The company operates at the intersection of consumer health and medical technology, using its hydrogel platform across wound care, dermatology and cosmetic applications. Its products are sold under its own brands and through partners, positioning NEXGEL as a niche materials specialist in both regulated medical and broader OTC markets.
Average Trading Volume: 56,205
Technical Sentiment Signal: Sell
Current Market Cap: $12.12M
For detailed information about NXGL stock, go to TipRanks’ Stock Analysis page.